Advisory Committee for Pharmaceutical Science
Pharmacology Toxicology Subcommittee Meeting
Topic # 1 Overview of Toxicogenomics at the Drug Development and Regulatory Interface
Lesko, LJ, et al Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol 43(4): 342-58, 2003
Woodcock, J., Drug development and regulation in the
age of pharmacogenomics, Presentation to the FDA
Topic # 2 Toxicogenomic Data Quality and Database Issues
Petricoin, EF III et al. Medical applications of microarray technologies: A regulatory science perspective. Nature Genetics. supplement 2002; 32:474-479.
Topic # 3 CDER FDA Product Review and Linking Toxicogenomics Data with Toxicology Outcome
Brazma, A. et al., Minimum information about a microarray experiment (MIAME) - toward standards for microarray data. Nature Genetics 2001; 29:365-371.
CDER Guidance for Industry. Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products. November 1995.